We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aimmune Reports Daily Palforzia Desensitizes Most Patients to Peanuts
Aimmune Reports Daily Palforzia Desensitizes Most Patients to Peanuts
Aimmune Therapeutics said that 80 percent of allergic patients in a trial of its oral immunotherapy Palforzia (peanut allergen powder-dnfp) were desensitized to peanut proteins.